What We're Reading: Page 379
Industry reads hand-picked by our editors
Feb 23, 2015
Feb 20, 2015
-
-
Forbes
Biotech battle: Regeneron's Eylea bests Genenetch's Lucentis in head-to-head
-
Why FDA's label expansion for Celgene's Revlimid could foretell a global sales surge
-
-
-
Why so little uptake of preventive Truvada in the at-risk gay community?
-
Gilead's Harvoni supplants Sovaldi as top-selling launch drug
-
AstraZeneca's plan to unite R&D hubs takes flight
-
-
Feb 19, 2015
-
CVS fires controversial warning shot in opening salvo of PCSK9 price wars
-
The more, the merrier? Endo also pursuing Salix Pharma bid
-
-
-
Inotek slashes share price ahead of IPO
-
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
-
GSK replaces US pharma ops head Connelly amid struggles
-
AstraZeneca's plan to unite R&D hubs takes flight
-
Shanghai official to serve 19 years over GSK bribery case
-
Feb 18, 2015
-
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
-
GSK replaces US pharma ops head Connelly amid struggles
-
-
Can AZ finally solidify a deal for its anti-infectives unit?
-
Profits fall for India's largest drug maker
-
NAFTA patent spat rages on between Canada and Lilly
-
-
Eisai, Pfizer, and Novartis meds get FDA love over the long weekend
-
-
Feb 17, 2015
-
-
Shire raises 2015 forecast on NPS acquisition
-
-
-
AZ to settle Nexium kickback case for $7.9M
-
Teva's internal probe turns up 'likely' corruption
-
Valeant arranges financing for potential Salix Pharma bid
-
Indian pharma giants scuffle to snap up injectables maker Claris
-
-
Feb 13, 2015
-
-
UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg
-
Hospira CEO's golden parachute for Pfizer deal: $80 million
-
-
-
GSK broadens vax portfolio with $190M GlycoVaxyn deal
-
Chinese researchers develop nanocarrier for pancreatic cancer drug
-
-
-
Riken stem cell saga continues as Obokata and other scientists face reprimands
Feb 12, 2015
-
Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again
-
Citi analyst: Humira biosims will hurt AbbVie sales more than you think
-
Nanotrending: FDA adopts another nanotech standard
-
Former Merck financial analyst to plead guilty to insider trading
-
-
-
Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too
-
-
US-EU trade agreement not likely until 2017, SOCMA says
-
Former MN gov demands more trial transparency at UMN in wake of '04 suicide
Previous
